Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 20 Issue 12, December 2014

In the liver of obese animals, endoplasmic reticulum (ER) structure is altered, resulting in a higher number of contact sites between ER and mitochondria (Mitochondria Associated Membranes, MAMs). In this issue, Arruda et al. (p 1427) report that heightened MAM formation results in mitochondrial calcium overload, compromised mitochondrial oxidative capacity and oxidative stress. Image depicts a transmission electron micrograph of a hepatocyte within the liver of an obese (ob/ob) mouse, which displays ER wrapped around mitochondria with ultrastructural alterations. Original image captured by Ana Paula Arruda.

Editorial

  • Investigational drugs can save or extend lives, and seriously ill patients not able to take part in clinical trials should have access to such drugs whenever possible. In a climate of increased public pressure for this access—often termed compassionate use—five states in the US have passed so-called 'right to try' legislation. These laws are ill advised, as they are not likely to substantially increase access and have the potential to compromise the clinical trial system.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

News in Brief

Top of page ⤴

News Feature

Top of page ⤴

News

  • Our list of newsmakers this year includes a range of nonconformists, from a scientist advocating population-wide genetic tests to a doctor who caused a stir while waiting for takeout food.

    • Manasi Vaidya
    • Shraddha Chakradhar
    News
  • At first glance, 2014 may seem like a year dominated by disease outbreaks, from polio's reemergence in parts of Asia to the Ebola epidemic that still continues to make headlines. But a closer look indicates 2014 was replete with regulatory rulings, big investments in genomic medicine and activism in the name of research funding.

    • Manasi Vaidya
    • Shraddha Chakradhar
    News
  • This year's most notable research included studies that opened new avenues for regenerative medicine, paved the way to editing out vulnerability to disease and unraveled the genetic complexities underlying diseases such as leukemia and schizophrenia. Here are some of the papers that captured our attention and moved their fields forward in 2014.

    • Amanda Keener
    News
  • This year's newsworthy drugs made major strides against infectious diseases, cancer and more. Some others received attention for controversies they stemmed or stomped. Here is a look at the therapies that leapt forward, some that are in limbo, and others that fell by the wayside.

    • Amanda Keener
    News
Top of page ⤴

Correspondence

Top of page ⤴

News & Views

  • Diffuse intrinsic pontine glioma is a uniformly lethal malignant tumor of infancy with no effective therapies. A new study reveals that inhibition of JMJD3 has robust antitumor activity in diffuse intrinsic pontine glioma xenografts.

    • Vijay Ramaswamy
    • Marc Remke
    • Michael D Taylor
    News & Views
  • Increasing evidence points to a role for the immune system in the regulation of metabolism. Two new studies in mice indicate treatment with interleukin-22 restores mucosal immunity in diabetes and alleviates metabolic disease, resulting in improved glycemic control.

    • Elise Dalmas
    • Marc Y Donath
    News & Views
  • Frontotemporal dementia (FTD) is a neurodegenerative disease that causes social dysfunction and other symptoms. A new study suggests that social dysfunction in FTD is due to decreased microRNA-124 expression and resulting changes in glutamate receptor composition in the prefrontal cortex.

    • Andrew E Arrant
    • Erik D Roberson
    News & Views
  • Vascular endothelial growth factor A (VEGF-A) is a potent proangiogenic cytokine elevated in patients with peripheral artery disease (PAD). A new study links impaired vascular regrowth in PAD to increased expression of an antiangiogenic splice variant of VEGF-A.

    • Joshua M Boucher
    • Victoria L Bautch
    News & Views
Top of page ⤴

Perspective

  • Understanding the regenerative capacity of the adult mammalian heart and the cell types involved is essential for developing therapies for cardiac repair.

    • Jop H van Berlo
    • Jeffery D Molkentin
    Perspective
Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Analysis

Top of page ⤴

Technical Report

Top of page ⤴

Search

Quick links